Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
about
Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed PatientsClinical use of HIV integrase inhibitors: a systematic review and meta-analysisThe RADAR study: week 48 safety and efficacy of RAltegravir combined with boosted DARunavir compared to tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. Impact on bone healthThe potential cost and benefits of raltegravir in simplified second-line therapy among HIV infected patients in Nigeria and South AfricaClinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy.Brief Report: Switch to Ritonavir-Boosted Atazanavir Plus Raltegravir in Virologically Suppressed Patients With HIV-1 Infection: A Randomized Pilot Study.Combination antiretroviral therapy with raltegravir leads to rapid immunologic reconstitution in treatment-naive patients with chronic HIV infection.Role of raltegravir in HIV-1 management.Virological efficacy and safety of antiretroviral therapy-switch to atazanavir-based regimen: a review of the literature.Switch strategies in antiretroviral therapy regimens.Integrase Strand Transfer Inhibitors in HIV Therapy.Pharmacokinetic and pharmacodynamic evaluation of raltegravir and experience from clinical trials in HIV-positive patients.Use of Integrase Inhibitors in HIV-Infected Children and Adolescents.Comparative effectiveness of tenofovir in treatment-naïve HIV-infected patients: systematic review and meta-analysis.Dual antiretroviral therapy for HIV infection.Backbones versus core agents in initial ART regimens: one game, two players.Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity.Nucleoside reverse transcriptase inhibitor-reducing strategies in HIV treatment: assessing the evidence.NRTI backbone in HIV treatment: will it remain relevant?HIV viral kinetics and T cell dynamics in antiretroviral naïve persons starting an integrase strand transfer inhibitor and protease inhibitor regimen.Efficacy of raltegravir-containing regimens in antiretroviral-naïve and -experienced individuals in routine clinical practice.Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study.Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial.British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015
P2860
Q26768591-E4926654-2E9E-4429-A715-89DB5777B08DQ28484930-4AED5FD9-D35D-43DD-B462-4997FA0C4BB3Q34110585-4B35E6D7-3EA2-496E-ADAF-89BA5EC392F5Q34606231-98E0DBD0-E01C-4DB3-8E8B-8050E852B3CEQ34736194-55AEE13C-0EDE-4DF5-878C-8007F189DBEEQ35035055-2DB4CBC2-77E0-4330-B561-CABBED9002EFQ36721002-975A21C3-2271-4098-8ABA-925ACAE9A82EQ37247467-6717462D-77F3-4381-93AB-05B21E5709BEQ38002011-38AA2392-1714-40D3-B36B-91F670FDB60BQ38050815-A7474801-B715-494C-93CE-50DFFBFDF5D0Q38235295-92E7904B-EAAF-4836-B79F-4803E43624DEQ38240974-AB95D562-273F-4352-A965-A7639595CC4CQ38527537-14287A21-70B7-4D5C-870A-1C31B76495A6Q38560855-D1C71AC4-F32C-41EA-9851-C601C9247382Q38591208-F7A9FB39-ADF2-405A-B022-AD435FCB5924Q38670305-E6030152-BFFB-4E16-9F83-ECF51DF0FEE8Q38690825-74B35C0F-5C87-49CB-A287-931FF2E3F9C5Q38985948-A1CEE7AC-A478-4978-8A40-BCB5E9220F01Q39453985-297D8C7A-8097-49E6-9D58-073FC8ACB838Q39533858-F06DAA30-1012-44CE-830D-2484D1C18037Q40353844-ADE48A9A-7602-4527-AD32-A1BE41AC28DAQ40474552-1824892F-B024-4E56-A273-C197D9A7113DQ41056086-04D1BA15-0B11-4E9A-9D52-217B966E064AQ47130269-578EAED7-6E63-4A65-B4A7-2664FAE29BFCQ57180790-9F21CB5A-504F-41E5-93C6-10DF803D7B17
P2860
Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Examination of noninferiority, ...... ogress study, 48-week results.
@en
Examination of noninferiority, ...... ogress study, 48-week results.
@nl
type
label
Examination of noninferiority, ...... ogress study, 48-week results.
@en
Examination of noninferiority, ...... ogress study, 48-week results.
@nl
prefLabel
Examination of noninferiority, ...... ogress study, 48-week results.
@en
Examination of noninferiority, ...... ogress study, 48-week results.
@nl
P2093
P2860
P356
P1433
P1476
Examination of noninferiority, ...... rogress study, 48-week results
@en
P2093
Adebayo Lawal
Angela M Nilius
Jacques Reynes
Joseph Gathe
Linda M Fredrick
Ruth Soto-Malave
Thomas J Podsadecki
P2860
P304
P356
10.1310/HCT1205-255
P577
2011-09-01T00:00:00Z